Jane Kilkenny named new VP of US MR business division at Siemens Healthineers

Michael Walter | | Health Imaging | Economics
Jane Kilkenny

Jane Kilkenney. Courtesy of Siemens Healthineers. 

Siemens Healthineers announced that Jane Kilkenny is the company’s new vice president of U.S. magnetic resonance (MR) business management, Health Imaging learned on Oct. 2 from a Siemens spokesman. 

Kilkenny has been with the company since 2001 and previously served as the country business lead for diagnostic imaging for Great Britain and Ireland at Siemens. She was the MR business manager for Great Britain.

Kilkenny, who studied imaging at the University of Lancaster in the U.K., also has experience as an MR radiologic technologist.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Related Content

Building a successful CCTA program: Physicians and healthcare executives to share advice
Shift toward imaging outside the hospital could save billions
Mexico, not China, is biggest tariff concern among radiology vendors
The impact of Trump tariffs on iodine contrast media costs
The biggest obstacles facing radiology business managers in 2025
Cardiology practices pay $17.7M to settle fraud allegations brought on by whistleblowers

Around the web

Cardiovascular Business
ASE updates recommendations for assessing right heart function in patients with pulmonary hypertension

The new guidelines were designed to ensure sonographers and other members of the heart team have the information they need to screen patients when appropriate and identify early warnings signs of PH. 

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
‘A significant milestone’: First US patients receive doses of new PET radiotracer for CAD

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care.